AMGEN INC AMGEN ORD (CDI) news, videos and press releases
For more news please use our advanced search feature.
AMGEN INC AMGEN ORD (CDI) - More news...
AMGEN INC AMGEN ORD (CDI) - More news...
- AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024
- AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
- AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
- AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
- AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
- AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS
- AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY
- AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
- AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
- AMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
- AMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO
- AMGEN TO HOST CONFERENCE CALL ON RARE DISEASE
- AMGEN TO PRESENT AT THE 34TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE
- AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
- AMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
- AMGEN TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
- AMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS® (SOTORASIB)
- AMGEN ANNOUNCES EXECUTIVE APPOINTMENTS TO ACCELERATE INNOVATION
- AMGEN TO SPONSOR THE IRISH OPEN
- AMGEN ANNOUNCES 2024 FIRST QUARTER DIVIDEND INCREASE TO $2.25 PER SHARE
- AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023
- AMGEN TO PRESENT AT THE EVERCORE ISI HEALTHCONX CONFERENCE
- AMGEN PRESENTS NEW CARDIOVASCULAR RESEARCH AT AHA 2023
- AMGEN PRESENTS NEW DATA FROM PHASE 2 TRIAL OF DAZODALIBEP IN SJÖGREN'S SYNDROME AT ACR 2023
- AMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA® (PEGLOTICASE)
- AMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO
- AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS
- AMGEN ANNOUNCES WEBCAST OF 2023 THIRD QUARTER FINANCIAL RESULTS
- AMGEN ANNOUNCES 2023 FOURTH QUARTER DIVIDEND
- AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER